HIFU is a cutting edge treatment that results in necrosis of cancer tissue after applying high-intensity focused ultrasound (HIFU) energy to a focused area with the action of thermal energy and cavitation.
For a long time, ultrasound has been playing an important role in diagnosis, but these days it's role has also expanded to include treatment. With the advancement of imaging technology, HIFU makes highly effective to destroy migrating cancer cells without surgery. Therefore, HIFU can be considered as ultrasonic version of three dimentional radiation such as cyber knife and gamma knife.
HIFU treatment device was first developed for transrectal ultrasound biopsy. And then the new treatment has been experimenting from outside the body by HIFU. In our clinic, we use the Ultrasound-guided 3rd generation FEP-BY02 HIFU Tumor Therapy System.
Using the ultrasound imagining part of the HIFU device it is possible to observe damaged areas in real time. This ability can also make follow-up screening easy and it is considered a big benefit that the damaged areas in abdominal organs, which are usually in motion, can be easily screened.
Our FEP‐BY02 HIFU is a fixed focus device focusing 251 ultrasonic transmission elements at 1.1 MHz lined up on 37 cm spherical body.
Many of HIFU is applied only from below whereas the HIFU which our clinic uses is possible to be applied both from above and below by using two devices.
For liver cancer and pancreatic cancer, it is actually applied about 99 % from above in order to be treated highly precisely. It takes time to treat and it is also difficult to target the area if applied only from below.
HIFU is a medical procedure which focuses ultrasound with high intensity inside of the body which results in necrosis of cancer tissue by way of thermal energy and cavitation.
HIFU destroys the size with 3 mm x 3 mm x 10 mm of cancer cells by a few second single dose irradiation which is generated by thermal energy on the targetted area.
The area which is irradiated by a single dose is limited to 3 mm x 3 mm x 10 mm.
Repositioning and repeated irradiation is used to cover a larger area to destroy all of the tumor area. The cancer cells are destroyed by repeatedly being irradiated.
There are two biological actions produced in the patient's body - thermal effect and non-thermal effect.
When ultrasound with the temperature of over 60 °C (140 °F) is applied to cancer cells for a few seconds, the cancer tissue will be coagulated and destroyed.
Ultrasound also generates a non-thermal effects which is called cavitation. Cavitation is the phenomenon by which air bubbles are generated when ultrasound is spotted. The shock wave generated when air bubbles burst or micro jet stream is also considered to kill cancer cells.
The energy level of HIFU is about 1000 times as big as ultrasound device for imaging. But compared to proton beam, x-ray or CT, it is extremely low and so it is said to be fairly safe. And there is no worry about radiation exposure.
The targeted area by a single irradiation is only limited to 3 mm x 3 mm x 10 mm. If there are cancer cells in the internal organ near the skin, it will cause skin burn due to skin temperature raised. So our FEP‐BY02 HIFU adopts the transducer with large diameter, and the safety is enhanced by widening the angle of incidence by 80 degrees.
In general, it takes about 1 hour and 30 minutes for a single treatment, which is performed 1 or 2 times.
Anaesthetic is not usually applied. This is a treatment uses ultrasound energy, so there is no limitation as with the use of radiation. HIFU treatment can be used repeatedly because there is no risk of radiation exposure.
Depending on the size and location of the cancer, various treatment will be examined, and generally, hospitalization is not required. But the contents of treatment, the dose and the need for hospitalization will vary depending on each patient's medical condition.
The significant use of Gd-EOB-DAPT MRI has enabled us to detect Hepatocellular carcinoma (HCC), the most common type of liver cancer, at earlier stage, which used to be difficult to be detected with dynamic CT. So the prompt measures for the treatment are being required. Under the circumstances, HIFU has made it possible to treat a patient with liver cancer of 1-2 cm big for about 1 hour without hospitalization. HIFU will be considered to be one of the leading treatments for HCC in Japan.
Number of treatments: 1 or more
Purchase your Colostrum MAF here using PayPal or credit card.Heart Pharmacy website
Thank you very much for your participation at the Saisei Mirai 2016 Integrative Medical Therapies conference in Osaka, held on Sunday 13th November 2016.2016 Integrative Medical Therapies conference - Osaka, Japan
Dr Toshio Inui
Dr. Toshio Inui gave a presentation of the electric field therapy and second-generation GcMAF and colostrum MAF at a conference which was held in Jakarta, Indonesia on July 22, 2016.
14 to 15-JUL-2016
Dr. Shinichiro Akiyama at International Pharmacy Conference, which was held in the United States Philadelphia, Pennsylvania on July 14 to 15, 2016, the Clinical experience of colostrum derived protein against solid cancer has been announced as the Keynote Speaker.
New research papers on Oral Colostrum GcMAF for Chronic Fatigue Syndrome (CFS) and serious infection published in Anticancer Research journal.Research paper
Clinical application of Second Generation GcMAF and oral GcMAF
Dr Toshio Inui
Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections (PDF)
Dr Toshio Inui
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy (PDF), PPT
Dr Toshio Inui
New research papers on GcMAF and integrative cancer immunotherapy treatment written in collaboration with the University of Tokushima, Kanazawa University and Kobe University Graduate School of Medicine researchers and Saisei Mirai published in Anticancer Research journal.Research paper
The results show that 2nd Generation GcMAF is stable for 1 year at 4 °C, for 14 days at room temperature (around 20 °C), and for 7 days at 40 °C.
See Research and references for more details on experiments on macrophage phagocytic activity and stability of our GcMAF.